Metoject (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, preventing the formation of tetrahydrofolate needed for DNA, RNA and protein synthesis. This limits the replication of rapidly dividing cells such as activated immune cells and cancer cells. Additionally, it raises extracellular adenosine, which contributes to its anti‑inflammatory properties.

The dose of Metoject is individualized by the prescribing clinician based on the specific indication, patient weight, renal and hepatic function, and response to therapy. Dosage adjustments are made according to laboratory monitoring and clinical assessment, and patients should follow the prescriber’s instructions precisely.

Methotrexate is classified as pregnancy category X because it is known to cause fetal malformations and embryotoxicity. It is contraindicated in pregnancy and women of child‑bearing potential must use effective contraception. Limited data exist for breastfeeding, and the drug is generally avoided due to potential infant exposure.

To order Metoject, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and necessary import documentation.

Compared with biologic DMARDs, methotrexate (Metoject) is a small‑molecule agent that is generally less expensive and administered by subcutaneous injection. It has a well‑established efficacy profile for rheumatoid arthritis and psoriasis, but may require more laboratory monitoring for hepatic and hematologic toxicity.

Metoject should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture and direct sunlight. Do not freeze the preparation, and keep it out of reach of children.

Metoject is given by subcutaneous injection, typically into the abdomen or thigh. The injection site should be rotated to reduce local irritation. Administration is performed by a healthcare professional or a trained patient following aseptic technique and the prescriber’s dosing schedule.

The most serious risks include severe liver toxicity or fibrosis, pulmonary fibrosis or interstitial pneumonitis, and bone‑marrow suppression that can lead to pancytopenia. These events are rare but require prompt medical attention and regular monitoring of liver function, lung status and blood counts.

Metoject is contraindicated in pregnant women, patients with severe renal or hepatic impairment, and individuals with known hypersensitivity to methotrexate. It should also be avoided in patients receiving live vaccines or those with uncontrolled infections, unless the prescriber determines the benefits outweigh the risks.